The Limits of Individualism: Potential Societal Harms from the EAP for Convalescent Plasma

Name / volume / issue


Page number


Primary author

David Magnus

Tag(s): Journal article


This issue features a set of articles addressing allocation issues for drugs for COVID-19 that have not been approved by the FDA but are available through either Emergency Use Authorization or Expanded Access Programs (EAP). Webb et al. (2020) propose a framework to guide these decisions. Of particular note, the authors point out that a requirement for EAP programs is that they do not interfere with clinical development, including clinical trials, and that the larger the number of participants, the greater the evidence required for an EAP.

Full text

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Privacy Policy. By closing this message, you are consenting to our use of cookies.